These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 3343839)

  • 21. Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
    Kaufmann M; Graf E; Jonat W; Eiermann W; Geberth M; Albert US; Gademann G; Conrad B; Stahl K; von Minckwitz G; Schumacher M;
    J Clin Oncol; 2005 Nov; 23(31):7842-8. PubMed ID: 16258087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.
    Rivkin SE; Green SJ; Lew D; Costanzi JJ; Athens JW; Osborne CK; Vaughn CB; Martino S
    Cancer; 2003 Jan; 97(1):21-9. PubMed ID: 12491501
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: final report after a 16-year median follow-up duration.
    Misset JL; di Palma M; Delgado M; Plagne R; Chollet P; Fumoleau P; Le Mevel B; Belpomme D; Guerrin J; Fargeot P; Metz R; Ithzaki M; Hill C; Mathé G
    J Clin Oncol; 1996 Apr; 14(4):1136-45. PubMed ID: 8648368
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer.
    Hartman AR; Fleming GF; Dillon JJ
    Clin Breast Cancer; 2001 Jul; 2(2):138-43; discussion 144. PubMed ID: 11899785
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endocrine versus endocrine plus five-drug chemotherapy in postmenopausal women with stage II estrogen receptor-positive breast cancer.
    Pearson OH; Hubay CA; Gordon NH; Marshall JS; Crowe JP; Arafah BM; McGuire W
    Cancer; 1989 Nov; 64(9):1819-23. PubMed ID: 2790695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant hormone treatment and chemotherapy in postmenopausal women with operable breast cancer: a retrospective analysis.
    Oriana S; Coradini D; Sasso GM; Di Fronzo G
    Anticancer Res; 1991; 11(6):2199-205. PubMed ID: 1776861
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined modality treatment of locally advanced breast cancer: adjuvant combination chemotherapy with and without doxorubicin.
    Casper ES; Guidera CA; Bosl GJ; Hakes TB; Kaufman RJ; Shurgot B; Kinne DW
    Breast Cancer Res Treat; 1987; 9(1):39-44. PubMed ID: 3593990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retreating recurrent breast cancer with the same CMF-containing regimen used as adjuvant therapy. The International Breast Cancer Study Group.
    Castiglione-Gertsch M; Tattersall M; Hacking A; Goldhirsch A; Gudgeon A; Gelber RD; Lindtner J; Coates A; Collins J; Isley M; Senn HJ; Rudenstam CM
    Eur J Cancer; 1997 Dec; 33(14):2321-5. PubMed ID: 9616275
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identifying good prognosis group of breast cancer patients with 1-3 positive axillary nodes for adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF) chemotherapy.
    Lin YC; Chen SC; Chang HK; Hsueh S; Tsai CS; Lo YF; Hwang TL; Chen MF
    Jpn J Clin Oncol; 2005 Sep; 35(9):514-9. PubMed ID: 16199422
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.
    Lancet; 1998 Sep; 352(9132):930-42. PubMed ID: 9752815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Responses to chemotherapy or chemohormonal therapy in advanced breast cancer patients treated previously with adjuvant chemotherapy. A subset analysis of CALGB Study 8081.
    Kardinal CG; Perry MC; Korzun AH; Rice MA; Ginsberg S; Wood WC
    Cancer; 1988 Feb; 61(3):415-9. PubMed ID: 3338011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984).
    Jones SE; Brooks RJ; Takasugi BJ; Garewal HS; Giordano GF; Ketchel SJ; Jackson R; Heusinkveld RS; Kemmer SR; Moon TE
    Recent Results Cancer Res; 1984; 96():133-40. PubMed ID: 6396766
    [No Abstract]   [Full Text] [Related]  

  • 33. Long term follow-up of women treated with 16-week, dose-intensive adjuvant chemotherapy for high risk breast carcinoma.
    Mikhak B; Zahurak M; Abeloff MD; Fetting JH; Davidson NE; Donehower RC; Waterfield W; Kennedy MJ
    Cancer; 1999 Feb; 85(4):899-904. PubMed ID: 10091768
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combined chemotherapy and radiotherapy for patients with breast cancer and extensive nodal involvement.
    Ung O; Langlands AO; Barraclough B; Boyages J
    J Clin Oncol; 1995 Feb; 13(2):435-43. PubMed ID: 7844606
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The response to further chemotherapy in patients with carcinoma of the breast who progressed while receiving adjuvant therapy.
    Morris DM; Elias EG; Didolkar MS; Brown SD
    J Surg Oncol; 1985 Jul; 29(3):154-7. PubMed ID: 3001423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of chemotherapy with chemohormonal therapy as first-line therapy for metastatic, hormone-sensitive breast cancer: An Eastern Cooperative Oncology Group study.
    Sledge GW; Hu P; Falkson G; Tormey D; Abeloff M
    J Clin Oncol; 2000 Jan; 18(2):262-6. PubMed ID: 10637238
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The importance of local-regional radiotherapy with conventional or high-dose chemotherapy in the management of breast cancer patients with > or = 10 positive axillary nodes.
    Jabro G; Wazer DE; Ruthazer R; Lum R; Sklar N; Goldman D; Enegess D; Erban J
    Int J Radiat Oncol Biol Phys; 1999 May; 44(2):273-80. PubMed ID: 10760419
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adjuvant systemic therapy for resectable breast cancer.
    Bonadonna G; Valagussa P
    J Clin Oncol; 1985 Feb; 3(2):259-75. PubMed ID: 3881562
    [No Abstract]   [Full Text] [Related]  

  • 39. Adjuvant therapy with tamoxifen in operable breast cancer. 10 year results of the Naples (GUN) study.
    Bianco AR; De Placido S; Gallo C; Pagliarulo C; Marinelli A; Petrella G; D'Istria M; Delrio G
    Lancet; 1988 Nov; 2(8620):1095-9. PubMed ID: 2903322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs.
    Buzdar AU; Hortobagyi GN; Smith TL; Kau S; Marcus C; Holmes FA; Hug V; Fraschini G; Ames FC; Martin RG
    Cancer; 1988 Nov; 62(10):2098-104. PubMed ID: 3179922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.